Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Clinical trial NCT05506969 · COMPLETED

Trial details

NCT number: NCT05506969
Sponsor: Dynavax Technologies Corporation
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Plague, Pneumonic Plague Vaccine-Preventable Diseases

Start date: 2022-08-09
Primary completion: 2023-10-03
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.